Evidence map›Paper›PMID 39844406›Full record

ArticleAnti-cancer agents in medicinal chemistry2025

Processed Products of

Xiaojuan Li, Xinle Tang, Liang Chen, Xingxing Cao, Reziya Ailimujiang, Qian Li, Feicui Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaojuan LiPharmacy Department of Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, 830054, China.
Xinle TangLaboratory Department of the Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830092, China.
Liang ChenPharmacy Department of Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Xingxing CaoPharmacy Department of Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, 830054, China.
Reziya AilimujiangPharmacy Department of Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, 830054, China.
Qian LiPharmacy Department of Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Feicui ZhaoPharmacy Department of Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, Urumqi, 830054, China.

Funding

2023 Autonomous Region-level Inheritor Studio of Famous Traditional Chinese Medicine Experts - Expert Feicui Zhao [New Health Science and Education] E2023, 93Department of Science and Technology of Xinjiang Uygur Autonomous Region 2022D01D24National Natural Science Foundation of China 82260766Xinjiang Uygur Autonomous Region University Research Program XJEDU2021I019
6 · The paper itself

Abstract

INTRODUCTION/

objectiveThe alkaloids of songorine, aconitine, and benzoylaconitine, as the processed products of

methodsA xenograft tumor model was constructed. Tumor volumes and weights were calculated. HE staining assessed the histopathological changes of tumors. Inflammatory factors were detected using ELISA. Gene and protein expressions of E-cadherin, N-cadherin, PIK3CA, and AKT1 proteins were measured using RT-qPCR and immunohistochemistry. Protein expressions of E-cadherin, N-cadherin, PIK3CA, AKT1, p-PIK3CA, and p- AKT1 proteins were detected using western blot analysis.

resultsSongorine, aconitine, and benzoylaconine significantly inhibited the growth of tumors as evidenced by decreased tumor volume and weight. The extent and scope of tumor cell necrosis were less in the songorine group compared to the vehicle group. Songorine, aconitine, and benzoylaconine significantly reduced IL-6, IL-1β, and TNF-α levels. Furthermore, songorine, aconitine, and benzoylecgonine induced down-regulation of

conclusionSongorine, aconitine, and benzoylaconine may inhibit ovarian cancer growth

Indexed as

AconitumAntineoplastic Agents, PhytogenicOvarian NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAconitineAnimalsCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMiceMice, Inbred BALB CMice, NudeMolecular StructureAconitineAntineoplastic Agents, PhytogenicPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAconitum soongaricum Stapf.epithelial-mesenchymal transformationLY294002ovarian cancerPI3K/AKT signal pathway.Processed product

Identifiers

PMID39844406

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.